A Phase 2 interventional study of Pembrolizumab and Lenvatinib in Advanced Solid Tumors, Triple Negative Breast Cancer and Ovarian Cancer, sponsored by Merck Sharp & Dohme LLC. Completed at 88 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-04.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 49 studies testing pembrolizumab in Triple Negative Breast Neoplasms — 17 open to participants now, 27 under way, 4 of them phase 3. pembrolizumab · Triple Negative Breast Neoplasms.
Among the 49 studies testing pembrolizumab in Triple Negative Breast Neoplasms, this one is the 8th largest by enrollment, is one of 2 that started in 2019, is one of 33 in phase 2, and was the 25th registered.
1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 445 are open to participants now.
Browse Triple Negative Breast Neoplasms studies →17 of the 49 studies testing pembrolizumab in Triple Negative Breast Neoplasms are open now, in 8 countries. Recruiting first, the newest first:
Medical University of South Carolina · Sites in United States
Ages 18+
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · Sites in Canada
Ages 18+
Medical University of South Carolina · Sites in United States
Ages 18+
UNICANCER · Sites in Belgium, France
Ages 18+
UNICANCER · Sites in France, Spain
Ages 18+
By country, each count listing its studies:
pembrolizumab: first FDA approval 2014 (KEYTRUDA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 332 Triple Negative Breast Neoplasms studies recruiting now, 232 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, pembrolizumab is the treatment under test here. Read study by study →
49 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 38 · Phase 3 7
First in 2010; this study’s year is marked. 2 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 611 is above the median of 60 across 1,053 interventional studies indexed under Triple Negative Breast Neoplasms.
Median enrollment 52 across the 49 interventional studies. Of the 17 that completed or were terminated, 13 (76%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 49 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
17 studies in Triple Negative Breast Neoplasms by Merck & Co., Inc: 3 open now, 3 under way, 3 of them phase 3. Of 13 finished, 11 (85%) have results posted.
Among the 17 studies in Triple Negative Breast Neoplasms by Merck & Co., Inc, this one is the 7th largest by enrollment, is one of 2 that started in 2019, is one of 5 in phase 2, and was the 9th registered.
Merck & Co., Inc’s Triple Negative Breast Neoplasms studies by the year they started, since 2014.
9 of the studies testing pembrolizumab in Triple Negative Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05645380University of Kansas Medical CenterNeoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC | 2026-12 |
| NCT04683679Memorial Sloan Kettering Cancer CenterA Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer | 2027-01 |
| NCT04468061Dana-Farber Cancer InstituteSacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC | 2027-04-01 |
| NCT06407310Tel Aviv Medical CenterNeoadjuvant Pembrolizumab, Carboplatin and Paclitaxel in Triple-negative Breast Cancer | 2027-04-01 |
| NCT04427293University of Illinois at ChicagoPreoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC) | 2027-07 |
Add all 9 to your calendar (.ics) → With an account.
Among the 49 studies testing pembrolizumab in Triple Negative Breast Neoplasms, from their registry updates:
Among Merck & Co., Inc’s 17 in Triple Negative Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the safety and efficacy of combination therapy with pembrolizumab (MK-3475) and lenvatinib (E7080/MK-7902) in participants with triple negative breast cancer (TNBC), ovarian cancer, gastric cancer, colorectal cancer (CRC), glioblastoma (GBM), biliary tract cancers (BTC), or pancreatic cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For Triple Negative Breast Cancer Participants:
For Ovarian Cancer Participants:
- Has primary ovarian cancer and has received 3 prior lines of therapy.
For Gastric Cancer Participants:
- Has received 2 prior lines of therapy. Note: Gastric cancer will include participants with both gastric and gastroesophageal junction (GEJ) adenocarcinoma. Participants with squamous cell carcinoma histology are not eligible
For Colorectal Cancer Participants:
- Has received 2 prior lines of therapy
For GBM Participants:
For Biliary Tract Cancer Participants:
For Pancreatic Cancer Participants:
Exclusion Criteria:
For GBM Participants:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W) plus lenvatinib 20 mg via oral capsule once a day (QD). Pembrolizumab will be administered for up to 35 cycles (up to 2 years). Lenvatinib will be administered until progressive disease or unacceptable toxicity (up to at least 2 years).
Biological: Pembrolizumab · Drug: Lenvatinib
Participants receive lenvatinib 24 mg via oral capsule QD, to be administered until progressive disease or unacceptable toxicity (up to at least 2 years).
Drug: Lenvatinib
Administered as an IV infusion on Day 1 Q3W.
Also known as: MK-3475, Keytruda®
Administered orally once a day during each 21-day cycle.
Also known as: MK-7902, E7080, LENVIMA™
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Investigator Assessment
ORR was defined as the percentage of participants who had a best overall response of either Complete Response (CR): Disappearance of all target lesions or Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions as assessed by RECIST 1.1. The percentage of participants who experienced a CR or PR as assessed by RECIST 1.1 by investigator assessment was presented. Per protocol, only data for Cohorts A and B were presented for this endpoint.
Time frame: Up to approximately 66 months
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) or Response Assessment in Neuro-Oncology (RANO) Criteria (for Glioblastoma Multiforma [GBM] Only), by Blinded Independent Central Review (BICR)
ORR was defined as the percentage of participants who had a best overall response of either Complete Response (CR): Disappearance of all target lesions or Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions as assessed by RECIST 1.1. For participants with GBM, response was assessed according to RANO criteria whereby ORR was defined as the percentage of participants who had a best overall response of either Complete response (CR): Disappearance of all target lesions or Partial response (PR): sum of products of diameters decreased by ≥50% from baseline value. The percentage of participants who experienced a CR or PR as assessed by RECIST 1.1 or RANO by BICR was presented. Per protocol, only data for Cohorts C, D1, D2, E, F, and G were presented for this endpoint.
Time frame: Up to approximately 66 months
Number of Participants With One or More Adverse Events (AEs)
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants with at least one or more AE is presented.
Time frame: Up to approximately 66 months
Number of Participants Who Discontinued From Study Treatment Due to an AE
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who discontinued from study treatment due to an AE is presented.
Time frame: Up to approximately 62 months
Disease Control Rate (DCR) Per RECIST 1.1 by Investigator Assessment
DCR was defined per RECIST 1.1 as the percentage of participants who have a Complete Response (CR: Disappearance of all target lesions) or Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) or Stable Disease (SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease \[PD: At least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD\]). Disease Control rate per RECIST 1.1 by investigator assessment is presented. Per protocol, only data for Cohorts A and B were presented for this endpoint.
Time frame: Up to approximately 66 months
Disease Control Rate (DCR) Per RECIST 1.1 or RANO Criteria (GBM Only) by BICR
DCR was defined per RECIST 1.1 as the percentage of participants who have a Complete Response (CR: Disappearance of all target lesions) or Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) or Stable Disease (SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease \[PD: At least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 mm\]). The appearance of one or more new lesions is also considered PD.\]). For participants with GBM, response was assessed according to RANO criteria whereby overall response was based on both radiographic response (CR: disappearance of all target lesions, PR: sum of products of diameters \[SPD\] decreased by ≥ 50% from baseline value and SD: SPD \<50% decreased from baseline, but \<25% increased from nadir) and clinical performance status with steroid dose information. The DCR as assessed by BICR is presented.
Time frame: Up to approximately 66 months
Duration of Response (DOR) Per RECIST 1.1 by Investigator Assessment
For participants who demonstrate a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR was defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. Duration of response per RECIST 1.1 by investigator assessment is presented. Per protocol, only data for Cohorts A and B were presented for this endpoint.
Time frame: Up to approximately 66 months
Duration of Response (DOR) Per RECIST 1.1 or RANO Criteria (GBM Only) by BICR
For participants who demonstrate a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR was defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. For participants with GBM, response will be assessed according to RANO criteria whereby overall RANO response is based on both radiographic response (CR: disappearance of all target lesions, PR: SPD decreased by ≥ 50% from baseline value) and clinical performance status with steroid dose information. DOR assessments were based on blinded central imaging review with confirmation.
Time frame: Up to approximately 66 months
Progression-Free Survival (PFS) Per RECIST 1.1 by Investigator Assessment
PFS was defined as the time from date of study treatment to the first documented progressive disease (PD) based on RECIST 1.1, modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. The percentage of participants who experienced PFS per RECIST 1.1 by investigator assessment is presented. Per protocol, only data for Cohorts A and B were presented for this endpoint.
Time frame: Up to approximately 66 months
Progression-Free Survival (PFS) Per RECIST 1.1 or RANO Criteria (GBM Only) by BICR
PFS was defined as the time from date of study treatment to the first documented progressive disease (PD) based on RECIST 1.1 (or RANO for GBM participants), modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. For participants with GBM, either radiological progression or clinical deterioration (not attributable to a nontumor-related cause) qualifies as PD. The percentage of participants who experienced PFS per RECIST 1.1 or RANO by BICR is presented. Per protocol, only data for Cohorts C, D1, D2, E, F, and G were presented for this endpoint.
Time frame: Up to approximately 66 months
Overall Survival (OS)
OS was defined as the time from the date of study treatment to the date of death due to any cause. Participants without documented death at the time of the final analysis were censored at the date of the last follow-up. The OS for all participants is presented.
Time frame: Up to approximately 66 months
Area Under the Concentration Curve at Steady State (AUCss) of Lenvatinib
Blood samples were collected at pre-specified timepoints to determine the AUCss in participants receiving Lenvatinib (Lenva) co-administered with Pembrolizumab (Pembro). AUCss was defined as a measure of drug exposure that was calculated as the product of plasma drug concentration and time after drug administration at steady state. AUCss determined by blood samples collected pre-dose and at designated timepoints post-dose are presented. Noncompartmental analysis was used to calculate AUC0ss for each participant. Mean and standard deviation of AUCss were calculated for each cohort. As specified in the protocol, pharmacokinetic analysis was not planned or conducted in Cohorts D2 and G.
Time frame: Cycle 1 Day 1: 0.5-4 hours and 6-10 hours post-dose; Cycle 1 Day 15: pre-dose and 2-12 hours post-dose; Cycle 2 Day 1: pre-dose, 0.5-4 hours, and 6-10 hours post-dose (up to approximately 23 days). Each cycle is 21 days.
This study was conducted at 85 centers in 17 countries.
| Milestone | Cohort A: Triple Negative Breast Cancer (Lenva + Pembro) | Cohort B: Ovarian Cancer (Lenva + Pembro) | Cohort C: Gastric Cancer (Lenva + Pembro) | Cohort D1: Colorectal Cancer (Lenva + Pembro) | Cohort D2: Colorectal Cancer (Lenva) | Cohort E: Glioblastoma Multiforma (Lenva + Pembro) | Cohort F: Biliary Tract Cancer (Lenva + Pembro) | Cohort G: Pancreatic Cancer (Lenva + Pembro) |
|---|---|---|---|---|---|---|---|---|
| Started | 31 | 31 | 102 | 107 | 32 | 102 | 103 | 103 |
| Treated | 31 | 31 | 99 | 105 | 30 | 101 | 102 | 103 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 31 | 31 | 102 | 107 | 32 | 102 | 103 | 103 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 3 | 0 | 2 | 2 | 3 |
| Withdrew: Sponsor decision | 3 | 3 | 3 | 6 | 0 | 3 | 3 | 2 |
| Withdrew: Death | 27 | 28 | 95 | 95 | 30 | 96 | 97 | 98 |
| Withdrew: Enrolled in error | 0 | 0 | 3 | 2 | 2 | 1 | 1 | 0 |
DCR was defined per RECIST 1.1 as the percentage of participants who have a Complete Response (CR: Disappearance of all target lesions) or Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) or Stable Disease (SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease \[PD: At least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD\]). Disease Control rate per RECIST 1.1 by investigator assessment is presented. Per protocol, only data for Cohorts A and B were presented for this endpoint.
| Percentage of Participants | Cohort A: Triple Negative Breast Cancer (Lenva + Pembro) | Cohort B: Ovarian Cancer (Lenva + Pembro) |
|---|---|---|
| Disease Control Rate (DCR) Per RECIST 1.1 by Investigator Assessment | 51.6 (33.1 to 69.8) | 77.4 (58.9 to 90.4) |
DCR was defined per RECIST 1.1 as the percentage of participants who have a Complete Response (CR: Disappearance of all target lesions) or Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) or Stable Disease (SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease \[PD: At least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 mm\]). The appearance of one or more new lesions is also considered PD.\]). For participants with GBM, response was assessed according to RANO criteria whereby overall response was based on both radiographic response (CR: disappearance of all target lesions, PR: sum of products of diameters \[SPD\] decreased by ≥ 50% from baseline value and SD: SPD \<50% decreased from baseline, but \<25% increased from nadir) and clinical performance status with steroid dose information. The DCR as assessed by BICR is presented.
| Percentage of Participants | Cohort C: Gastric Cancer (Lenva + Pembro) | Cohort D1: Colorectal Cancer (Lenva + Pembro) | Cohort D2: Colorectal Cancer (Lenva) | Cohort E: Glioblastoma Multiforma (Lenva + Pembro) | Cohort F: Biliary Tract Cancer (Lenva + Pembro) | Cohort G: Pancreatic Cancer (Lenva + Pembro) |
|---|---|---|---|---|---|---|
| Disease Control Rate (DCR) Per RECIST 1.1 or RANO Criteria (GBM Only) by BICR | 53.5 (43.2 to 63.6) | 52.4 (42.4 to 62.2) | 56.7 (37.4 to 74.5) | 57.4 (47.2 to 67.2) | 64.7 (54.6 to 73.9) | 37.9 (28.5 to 48.0) |
For participants who demonstrate a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR was defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. Duration of response per RECIST 1.1 by investigator assessment is presented. Per protocol, only data for Cohorts A and B were presented for this endpoint.
| Months | Cohort A: Triple Negative Breast Cancer (Lenva + Pembro) | Cohort B: Ovarian Cancer (Lenva + Pembro) |
|---|---|---|
| Duration of Response (DOR) Per RECIST 1.1 by Investigator Assessment | 22.9 (4.2 to NA) | 15.3 (6.4 to NA) |
For participants who demonstrate a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR was defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. For participants with GBM, response will be assessed according to RANO criteria whereby overall RANO response is based on both radiographic response (CR: disappearance of all target lesions, PR: SPD decreased by ≥ 50% from baseline value) and clinical performance status with steroid dose information. DOR assessments were based on blinded central imaging review with confirmation.
| Months | Cohort C: Gastric Cancer (Lenva + Pembro) | Cohort D1: Colorectal Cancer (Lenva + Pembro) | Cohort D2: Colorectal Cancer (Lenva) | Cohort E: Glioblastoma Multiforma (Lenva + Pembro) | Cohort F: Biliary Tract Cancer (Lenva + Pembro) | Cohort G: Pancreatic Cancer (Lenva + Pembro) |
|---|---|---|---|---|---|---|
| Duration of Response (DOR) Per RECIST 1.1 or RANO Criteria (GBM Only) by BICR | 8.3 (4.2 to NA) | 8.3 (4.2 to 18.5) | NA (NA to NA) | 4.6 (3.2 to 15.6) | 6.2 (4.2 to 7.1) | 5.8 (2.7 to NA) |
PFS was defined as the time from date of study treatment to the first documented progressive disease (PD) based on RECIST 1.1, modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. The percentage of participants who experienced PFS per RECIST 1.1 by investigator assessment is presented. Per protocol, only data for Cohorts A and B were presented for this endpoint.
| Months | Cohort A: Triple Negative Breast Cancer (Lenva + Pembro) | Cohort B: Ovarian Cancer (Lenva + Pembro) |
|---|---|---|
| Progression-Free Survival (PFS) Per RECIST 1.1 by Investigator Assessment | 4.2 (1.7 to 6.3) | 6.1 (4.1 to 9.4) |
PFS was defined as the time from date of study treatment to the first documented progressive disease (PD) based on RECIST 1.1 (or RANO for GBM participants), modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. For participants with GBM, either radiological progression or clinical deterioration (not attributable to a nontumor-related cause) qualifies as PD. The percentage of participants who experienced PFS per RECIST 1.1 or RANO by BICR is presented. Per protocol, only data for Cohorts C, D1, D2, E, F, and G were presented for this endpoint.
| Months | Cohort C: Gastric Cancer (Lenva + Pembro) | Cohort D1: Colorectal Cancer (Lenva + Pembro) | Cohort D2: Colorectal Cancer (Lenva) | Cohort E: Glioblastoma Multiforma (Lenva + Pembro) | Cohort F: Biliary Tract Cancer (Lenva + Pembro) | Cohort G: Pancreatic Cancer (Lenva + Pembro) |
|---|---|---|---|---|---|---|
| Progression-Free Survival (PFS) Per RECIST 1.1 or RANO Criteria (GBM Only) by BICR | 3.5 (2.3 to 4.1) | 3.4 (2.1 to 4.1) | 3.4 (2.1 to 4.8) | 3.0 (2.8 to 4.1) | 4.1 (3.6 to 5.9) | 2.1 (2.1 to 3.1) |
OS was defined as the time from the date of study treatment to the date of death due to any cause. Participants without documented death at the time of the final analysis were censored at the date of the last follow-up. The OS for all participants is presented.
| Months | Cohort A: Triple Negative Breast Cancer (Lenva + Pembro) | Cohort B: Ovarian Cancer (Lenva + Pembro) | Cohort C: Gastric Cancer (Lenva + Pembro) | Cohort D1: Colorectal Cancer (Lenva + Pembro) | Cohort D2: Colorectal Cancer (Lenva) | Cohort E: Glioblastoma Multiforma (Lenva + Pembro) | Cohort F: Biliary Tract Cancer (Lenva + Pembro) | Cohort G: Pancreatic Cancer (Lenva + Pembro) |
|---|---|---|---|---|---|---|---|---|
| Overall Survival (OS) | 11.4 (4.1 to 21.7) | 21.3 (11.7 to 32.3) | 4.7 (3.8 to 6.1) | 8.7 (7.0 to 10.0) | 7.9 (5.6 to 14.9) | 8.6 (7.4 to 10.8) | 7.9 (5.6 to 9.5) | 4.3 (3.8 to 5.4) |
Blood samples were collected at pre-specified timepoints to determine the AUCss in participants receiving Lenvatinib (Lenva) co-administered with Pembrolizumab (Pembro). AUCss was defined as a measure of drug exposure that was calculated as the product of plasma drug concentration and time after drug administration at steady state. AUCss determined by blood samples collected pre-dose and at designated timepoints post-dose are presented. Noncompartmental analysis was used to calculate AUC0ss for each participant. Mean and standard deviation of AUCss were calculated for each cohort. As specified in the protocol, pharmacokinetic analysis was not planned or conducted in Cohorts D2 and G.
| ng*hr/mL | Cohort A: Triple Negative Breast Cancer (Lenva + Pembro) | Cohort B: Ovarian Cancer (Lenva + Pembro) | Cohort C: Gastric Cancer (Lenva + Pembro) | Cohort D1: Colorectal Cancer (Lenva + Pembro) | Cohort E: Glioblastoma Multiforma (Lenva + Pembro) | Cohort F: Biliary Tract Cancer (Lenva + Pembro) |
|---|---|---|---|---|---|---|
| Area Under the Concentration Curve at Steady State (AUCss) of Lenvatinib | 3253 ± 1029 | 3145 ± 984 | 2392 ± 803 | 2994 ± 1143 | 2617 ± 804 | 2886 ± 838 |
ORR was defined as the percentage of participants who had a best overall response of either Complete Response (CR): Disappearance of all target lesions or Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions as assessed by RECIST 1.1. The percentage of participants who experienced a CR or PR as assessed by RECIST 1.1 by investigator assessment was presented. Per protocol, only data for Cohorts A and B were presented for this endpoint.
| Percentage of Participants | Cohort A: Triple Negative Breast Cancer (Lenva + Pembro) | Cohort B: Ovarian Cancer (Lenva + Pembro) |
|---|---|---|
| Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Investigator Assessment | 22.6 (9.6 to 41.1) | 25.8 (11.9 to 44.6) |
ORR was defined as the percentage of participants who had a best overall response of either Complete Response (CR): Disappearance of all target lesions or Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions as assessed by RECIST 1.1. For participants with GBM, response was assessed according to RANO criteria whereby ORR was defined as the percentage of participants who had a best overall response of either Complete response (CR): Disappearance of all target lesions or Partial response (PR): sum of products of diameters decreased by ≥50% from baseline value. The percentage of participants who experienced a CR or PR as assessed by RECIST 1.1 or RANO by BICR was presented. Per protocol, only data for Cohorts C, D1, D2, E, F, and G were presented for this endpoint.
| Percentage of Participants | Cohort C: Gastric Cancer (Lenva + Pembro) | Cohort D1: Colorectal Cancer (Lenva + Pembro) | Cohort D2: Colorectal Cancer (Lenva) | Cohort E: Glioblastoma Multiforma (Lenva + Pembro) | Cohort F: Biliary Tract Cancer (Lenva + Pembro) | Cohort G: Pancreatic Cancer (Lenva + Pembro) |
|---|---|---|---|---|---|---|
| Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) or Response Assessment in Neuro-Oncology (RANO) Criteria (for Glioblastoma Multiforma [GBM] Only), by Blinded Independent Central Review (BICR) | 15.2 (8.7 to 23.8) | 14.3 (8.2 to 22.5) | 6.7 (0.8 to 22.1) | 21.8 (14.2 to 31.1) | 17.6 (10.8 to 26.4) | 7.8 (3.4 to 14.7) |
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants with at least one or more AE is presented.
| Participants | Cohort A: Triple Negative Breast Cancer (Lenva + Pembro) | Cohort B: Ovarian Cancer (Lenva + Pembro) | Cohort C: Gastric Cancer (Lenva + Pembro) | Cohort D1: Colorectal Cancer (Lenva + Pembro) | Cohort D2: Colorectal Cancer (Lenva) | Cohort E: Glioblastoma Multiforma (Lenva + Pembro) | Cohort F: Biliary Tract Cancer (Lenva + Pembro) | Cohort G: Pancreatic Cancer (Lenva + Pembro) |
|---|---|---|---|---|---|---|---|---|
| Number of Participants With One or More Adverse Events (AEs) | 31 | 31 | 97 | 104 | 30 | 101 | 102 | 103 |
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who discontinued from study treatment due to an AE is presented.
| Participants | Cohort A: Triple Negative Breast Cancer (Lenva + Pembro) | Cohort B: Ovarian Cancer (Lenva + Pembro) | Cohort C: Gastric Cancer (Lenva + Pembro) | Cohort D1: Colorectal Cancer (Lenva + Pembro) | Cohort D2: Colorectal Cancer (Lenva) | Cohort E: Glioblastoma Multiforma (Lenva + Pembro) | Cohort F: Biliary Tract Cancer (Lenva + Pembro) | Cohort G: Pancreatic Cancer (Lenva + Pembro) |
|---|---|---|---|---|---|---|---|---|
| Number of Participants Who Discontinued From Study Treatment Due to an AE | 5 | 11 | 23 | 19 | 4 | 11 | 20 | 19 |
Collected over Up to approximately 66 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort A: Triple Negative Breast Cancer (Lenva + Pembro) | 27/31 (87.1%) | 16/31 (51.6%) | 30/31 (96.8%) |
| Cohort B: Ovarian Cancer (Lenva + Pembro) | 28/31 (90.3%) | 19/31 (61.3%) | 31/31 (100%) |
| Cohort C: Gastric Cancer (Lenva + Pembro) | 97/102 (95.1%) | 57/99 (57.6%) | 95/99 (96%) |
| Cohort D1: Colorectal Cancer (Lenva + Pembro) | 97/107 (90.7%) | 55/105 (52.4%) | 103/105 (98.1%) |
| Cohort D2: Colorectal Cancer (Lenva) | 30/32 (93.8%) | 12/30 (40%) | 29/30 (96.7%) |
| Cohort E: Glioblastoma Multiforma (Lenva + Pembro) | 99/102 (97.1%) | 30/101 (29.7%) | 98/101 (97%) |
| Cohort F: Biliary Tract Cancer (Lenva + Pembro) | 98/103 (95.1%) | 62/102 (60.8%) | 100/102 (98%) |
| Cohort G: Pancreatic Cancer (Lenva + Pembro) | 101/103 (98.1%) | 49/103 (47.6%) | 101/103 (98.1%) |
| Event | Cohort A: Triple Negative Breast Cancer (Lenva + Pembro) | Cohort B: Ovarian Cancer (Lenva + Pembro) | Cohort C: Gastric Cancer (Lenva + Pembro) | Cohort D1: Colorectal Cancer (Lenva + Pembro) | Cohort D2: Colorectal Cancer (Lenva) | Cohort E: Glioblastoma Multiforma (Lenva + Pembro) | Cohort F: Biliary Tract Cancer (Lenva + Pembro) | Cohort G: Pancreatic Cancer (Lenva + Pembro) |
|---|---|---|---|---|---|---|---|---|
| Intestinal obstructionGastrointestinal disorders | 0/31 | 3/31 | 1/99 | 3/105 | 0/30 | 0/101 | 0/102 | 0/103 |
| PyrexiaGeneral disorders | 0/31 | 2/31 | 1/99 | 2/105 | 0/30 | 4/101 | 7/102 | 1/103 |
| DiarrhoeaGastrointestinal disorders | 1/31 | 2/31 | 3/99 | 3/105 | 2/30 | 0/101 | 2/102 | 0/103 |
| HyperbilirubinaemiaHepatobiliary disorders | 0/31 | 0/31 | 1/99 | 0/105 | 2/30 | 0/101 | 0/102 | 0/103 |
| VomitingGastrointestinal disorders | 0/31 | 2/31 | 2/99 | 1/105 | 0/30 | 1/101 | 2/102 | 1/103 |
| CholecystitisHepatobiliary disorders | 0/31 | 2/31 | 0/99 | 0/105 | 1/30 | 0/101 | 1/102 | 0/103 |
| PneumoniaInfections and infestations | 1/31 | 2/31 | 2/99 | 1/105 | 0/30 | 1/101 | 2/102 | 1/103 |
| Urinary tract infectionInfections and infestations | 0/31 | 2/31 | 0/99 | 3/105 | 0/30 | 1/101 | 0/102 | 1/103 |
| HyponatraemiaMetabolism and nutrition disorders | 1/31 | 2/31 | 0/99 | 1/105 | 0/30 | 0/101 | 2/102 | 0/103 |
| HeadacheNervous system disorders | 0/31 | 2/31 | 0/99 | 0/105 | 0/30 | 0/101 | 0/102 | 0/103 |
| Event | Cohort A: Triple Negative Breast Cancer (Lenva + Pembro) | Cohort B: Ovarian Cancer (Lenva + Pembro) | Cohort C: Gastric Cancer (Lenva + Pembro) | Cohort D1: Colorectal Cancer (Lenva + Pembro) | Cohort D2: Colorectal Cancer (Lenva) | Cohort E: Glioblastoma Multiforma (Lenva + Pembro) | Cohort F: Biliary Tract Cancer (Lenva + Pembro) | Cohort G: Pancreatic Cancer (Lenva + Pembro) |
|---|---|---|---|---|---|---|---|---|
| HypertensionVascular disorders | 16/31 | 21/31 | 37/99 | 59/105 | 17/30 | 51/101 | 58/102 | 55/103 |
| DiarrhoeaGastrointestinal disorders | 14/31 | 19/31 | 30/99 | 47/105 | 16/30 | 26/101 | 42/102 | 25/103 |
| NauseaGastrointestinal disorders | 13/31 | 15/31 | 31/99 | 34/105 | 5/30 | 19/101 | 37/102 | 37/103 |
| Decreased appetiteMetabolism and nutrition disorders | 9/31 | 15/31 | 30/99 | 46/105 | 6/30 | 19/101 | 37/102 | 33/103 |
| HypothyroidismEndocrine disorders | 14/31 | 14/31 | 25/99 | 46/105 | 12/30 | 28/101 | 34/102 | 28/103 |
| FatigueGeneral disorders | 13/31 | 14/31 | 21/99 | 41/105 | 9/30 | 20/101 | 40/102 | 31/103 |
| VomitingGastrointestinal disorders | 10/31 | 13/31 | 15/99 | 26/105 | 8/30 | 13/101 | 20/102 | 19/103 |
| ProteinuriaRenal and urinary disorders | 6/31 | 13/31 | 12/99 | 39/105 | 11/30 | 12/101 | 23/102 | 22/103 |
| DysphoniaRespiratory, thoracic and mediastinal disorders | 5/31 | 3/31 | 20/99 | 21/105 | 12/30 | 11/101 | 31/102 | 17/103 |
| Blood alkaline phosphatase increasedInvestigations | 2/31 | 6/31 | 14/99 | 13/105 | 11/30 | 4/101 | 14/102 | 9/103 |
| Age, Categorical(Participants) | Cohort A: Triple Negative Breast Cancer (Lenva + Pembro) | Cohort B: Ovarian Cancer (Lenva + Pembro) | Cohort C: Gastric Cancer (Lenva + Pembro) | Cohort D1: Colorectal Cancer (Lenva + Pembro) | Cohort D2: Colorectal Cancer (Lenva) | Cohort E: Glioblastoma Multiforma (Lenva + Pembro) | Cohort F: Biliary Tract Cancer (Lenva + Pembro) | Cohort G: Pancreatic Cancer (Lenva + Pembro) | Total |
|---|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 25 | 18 | 68 | 71 | 25 | 83 | 52 | 56 | 398 |
| >=65 years | 6 | 13 | 34 | 36 | 7 | 19 | 51 | 47 | 213 |
| Sex: Female, Male(Participants) | Cohort A: Triple Negative Breast Cancer (Lenva + Pembro) | Cohort B: Ovarian Cancer (Lenva + Pembro) | Cohort C: Gastric Cancer (Lenva + Pembro) | Cohort D1: Colorectal Cancer (Lenva + Pembro) | Cohort D2: Colorectal Cancer (Lenva) | Cohort E: Glioblastoma Multiforma (Lenva + Pembro) | Cohort F: Biliary Tract Cancer (Lenva + Pembro) | Cohort G: Pancreatic Cancer (Lenva + Pembro) | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 31 | 31 | 30 | 32 | 14 | 38 | 53 | 42 | 271 |
| Male | 0 | 0 | 72 | 75 | 18 | 64 | 50 | 61 | 340 |
| Ethnicity (NIH/OMB)(Participants) | Cohort A: Triple Negative Breast Cancer (Lenva + Pembro) | Cohort B: Ovarian Cancer (Lenva + Pembro) | Cohort C: Gastric Cancer (Lenva + Pembro) | Cohort D1: Colorectal Cancer (Lenva + Pembro) | Cohort D2: Colorectal Cancer (Lenva) | Cohort E: Glioblastoma Multiforma (Lenva + Pembro) | Cohort F: Biliary Tract Cancer (Lenva + Pembro) | Cohort G: Pancreatic Cancer (Lenva + Pembro) | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 6 | 2 | 17 | 19 | 9 | 13 | 9 | 16 | 91 |
| Not Hispanic or Latino | 19 | 23 | 64 | 77 | 23 | 73 | 76 | 86 | 441 |
| Unknown or Not Reported | 6 | 6 | 21 | 11 | 0 | 16 | 18 | 1 | 79 |
| Race (NIH/OMB)(Participants) | Cohort A: Triple Negative Breast Cancer (Lenva + Pembro) | Cohort B: Ovarian Cancer (Lenva + Pembro) | Cohort C: Gastric Cancer (Lenva + Pembro) | Cohort D1: Colorectal Cancer (Lenva + Pembro) | Cohort D2: Colorectal Cancer (Lenva) | Cohort E: Glioblastoma Multiforma (Lenva + Pembro) | Cohort F: Biliary Tract Cancer (Lenva + Pembro) | Cohort G: Pancreatic Cancer (Lenva + Pembro) | Total |
|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 5 | 4 | 11 | 17 | 2 | 17 | 18 | 8 | 82 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Black or African American | 0 | 0 | 2 | 4 | 2 | 0 | 1 | 2 | 11 |
| White | 22 | 23 | 70 | 71 | 25 | 72 | 71 | 90 | 444 |
| More than one race | 0 | 0 | 2 | 4 | 3 | 1 | 0 | 3 | 13 |
| Unknown or Not Reported | 4 | 4 | 17 | 11 | 0 | 11 | 13 | 0 | 60 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Feb 2019 to primary completion in Oct 2024, 68 months.
Results were first posted in Nov 2025, 1 year after primary completion.
Of 255 phase 2 interventional studies under Triple Negative Breast Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 94. This study's 68 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Pembrolizumab · Lenvatinib
Triple Negative Breast Neoplasms →